| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Meera Shah, Marcello C Laurenti, Chiara Dalla Man, Jing Ma, Claudio Cobelli, Robert A Rizza, Adrian Vell. Contribution of endogenous glucagon-like peptide-1 to changes in glucose metabolism and islet function in people with type 2 diabetes four weeks after Roux-en-Y gastric bypass (RYGB). Metabolism: clinical and experimental. vol 93. 2019-12-03. PMID:30586575. |
glucagon-like peptide-1 (glp-1) is an insulin secretagogue which is elevated after roux-en-y gastric bypass (rygb). |
2019-12-03 |
2023-08-13 |
Not clear |
| Yangfeng Hou, Wenjing Fan, Wenling Yang, Abdul Qadir Samdani, Ampadu Okyere Jackson, Shunlin Q. Farnesoid X receptor: An important factor in blood glucose regulation. Clinica chimica acta; international journal of clinical chemistry. vol 495. 2019-12-02. PMID:30910597. |
this review summarises recent studies on fxr regulation of bg balance via bile acid regulation, lowering glucagon-like peptide-1 (glp-1), inhibiting gluconeogenesis, increasing insulin secretion and enhancing insulin sensitivity. |
2019-12-02 |
2023-08-13 |
Not clear |
| James E Fole. Insights Into GLP-1 and GIP Actions Emerging From Vildagliptin Mechanism Studies in Man. Frontiers in endocrinology. vol 10. 2019-12-01. PMID:31781045. |
vildagliptin blocks glucagon like peptide-1 (glp-1) and glucose-dependent insulinotropic polypeptide (gip) inactivation of the meal induced increases in glp-1 and gip so that elevated glp-1 and gip levels are maintained over 24 h. the primary insulin secretion effect of vildagliptin is to improve the impaired sensitivity of the β-cells to glucose in subjects with impaired fasting glucose (ifg) and impaired glucose tolerance (igt) and in patients with type 2 diabetes mellitus (t2dm); this effect was seen acutely and maintained over at least 2 years in patients with t2dm. |
2019-12-01 |
2023-08-13 |
human |
| Sandra Handgraaf, Rodolphe Dusaulcy, Florian Visentin, Jacques Philippe, Yvan Gosmai. 17-β Estradiol regulates proglucagon-derived peptide secretion in mouse and human α- and L cells. JCI insight. vol 3. issue 7. 2019-11-25. PMID:29618657. |
we conclude that e2 directly controls both α- and l cells to increase glp-1 secretion, in addition to its effects on insulin and glucagon secretion, highlighting the potential beneficial role of the estrogenic pathway and, more particularly, of erβ agonists to prevent type 2 diabetes. |
2019-11-25 |
2023-08-13 |
mouse |
| Hols. Glucagon-like Peptide 1 (GLP-1): An Intestinal Hormone, Signalling Nutritional Abundance, with an Unusual Therapeutic Potential. Trends in endocrinology and metabolism: TEM. vol 10. issue 6. 2019-11-20. PMID:10407397. |
the incretin hormone, glucagon-like peptide 1 (glp-1) has many actions; namely: (1) it enhances all steps of insulin biosynthesis and potentiates glucose-induced secretion; (2) it seems to have trophic effects on pancreatic cells; (3) it inhibits glucagon secretion; (4) it inhibits hepatic glucose production and lowers blood glucose, but does not produce severe hypoglycaemia; (5) it inhibits postprandial gastrointestinal motility and secretion; and (6) it reduces appetite and food intake. |
2019-11-20 |
2023-08-12 |
Not clear |
| Margaret T Behme, John Dupré, Thomas J McDonal. Glucagon-like peptide 1 improved glycemic control in type 1 diabetes. BMC endocrine disorders. vol 3. issue 1. 2019-11-20. PMID:12697069. |
background: glucagon-like peptide-1 (glp-1) and its agonists are under assessment in treatment of type 2 diabetes, by virtue of their antidiabetic actions, which include stimulation of insulin secretion, inhibition of glucagon release, and delay of gastric emptying. |
2019-11-20 |
2023-08-12 |
Not clear |
| Margaret T Behme, John Dupré, Thomas J McDonal. Glucagon-like peptide 1 improved glycemic control in type 1 diabetes. BMC endocrine disorders. vol 3. issue 1. 2019-11-20. PMID:12697069. |
we examined the potential of glp-1 to improve glycemic control in type 1 diabetes with no endogenous insulin secretion. |
2019-11-20 |
2023-08-12 |
Not clear |
| Margaret T Behme, John Dupré, Thomas J McDonal. Glucagon-like peptide 1 improved glycemic control in type 1 diabetes. BMC endocrine disorders. vol 3. issue 1. 2019-11-20. PMID:12697069. |
in outside-hospital studies, glp-1 or vehicle was self-administered double-blind before meals with usual insulin for five consecutive days by five males and three females with well-controlled c-peptide-negative type 1 diabetes. |
2019-11-20 |
2023-08-12 |
Not clear |
| Margaret T Behme, John Dupré, Thomas J McDonal. Glucagon-like peptide 1 improved glycemic control in type 1 diabetes. BMC endocrine disorders. vol 3. issue 1. 2019-11-20. PMID:12697069. |
conclusion: we have demonstrated that subcutaneous glp-1 can improve glucose control in type 1 diabetes without adverse effects when self-administered before meals with usual insulin during established intensive insulin treatment programs. |
2019-11-20 |
2023-08-12 |
Not clear |
| Rodrigo O Moreira, Stella C Campos, Ana L Solder. Type 2 Diabetes Mellitus and Alzheimer's Disease: from physiopathology to treatment implications. Diabetes/metabolism research and reviews. 2019-11-20. PMID:23868462. |
indeed, manuscripts investigating the effects of metformin, thiazolinediones, leptin, glp-1 therapies, insulin and bariatric surgery in cognition and ad have been published with very promising results, and may indicate an alternative approach for these patients. |
2019-11-20 |
2023-08-12 |
Not clear |
| Jerry D Meece, Teresa L Pearson, Linda M Simineri. Complementary Approaches to Improving Glucose Control-Insulin and Incretins: Patient Case Studies in Action. The Diabetes educator. vol 40. issue 1 suppl. 2019-11-20. PMID:24841710. |
search terms included insulin, dpp-4 inhibitors, glp-1 receptor agonists, hypoglycemia, and weight gain. |
2019-11-20 |
2023-08-13 |
Not clear |
| Alena Adamíková, Jaroslav Rybk. [Long-term acting insulin analogues and the risks of hypoglycemic incidence]. Vnitrni lekarstvi. vol 60. issue 9. 2019-11-20. PMID:25294753. |
a therapy of basal insulin analogues, linked to a low risk rate of hypoglycemic incidence, enables combination with oral antidiabetic drugs and glp-1 receptor agonists.key words: basal insulin analogues - hypoglycemia - type 2 diabetes mellitus. |
2019-11-20 |
2023-08-13 |
Not clear |
| Donald K Layman, Tracy G Anthony, Blake B Rasmussen, Sean H Adams, Christopher J Lynch, Grant D Brinkworth, Teresa A Davi. Defining meal requirements for protein to optimize metabolic roles of amino acids. The American journal of clinical nutrition. vol 101. issue 6. 2019-11-20. PMID:25926513. |
recent research has focused on amino acids as metabolic signals that influence the rate of protein synthesis, inflammation responses, mitochondrial activity, and satiety, exerting their influence through signaling systems including mammalian/mechanistic target of rapamycin complex 1 (mtorc1), general control nonrepressed 2 (gcn2), glucagon-like peptide 1 (glp-1), peptide yy (pyy), serotonin, and insulin. |
2019-11-20 |
2023-08-13 |
Not clear |
| Kentaro Tsuboi, Hiroki Mizukami, Wataru Inaba, Masayuki Baba, Soroku Yagihash. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses development of neuropathy in diabetic rodents: effects on peripheral sensory nerve function, structure and molecular changes. Journal of neurochemistry. vol 136. issue 4. 2019-11-20. PMID:26603140. |
drg from gk and stz-diabetic mice served for the analyses of glp-1 and insulin signaling. |
2019-11-20 |
2023-08-13 |
mouse |
| Kentaro Tsuboi, Hiroki Mizukami, Wataru Inaba, Masayuki Baba, Soroku Yagihash. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses development of neuropathy in diabetic rodents: effects on peripheral sensory nerve function, structure and molecular changes. Journal of neurochemistry. vol 136. issue 4. 2019-11-20. PMID:26603140. |
as results, vg treatment improved glucose intolerance and increased serum insulin and glp-1 in gk accompanied by the amelioration of delayed ncv and neuronal atrophy, reduced calcitonin-gene-related peptide expressions and intraepidermal nerve fiber density. |
2019-11-20 |
2023-08-13 |
mouse |
| Kentaro Tsuboi, Hiroki Mizukami, Wataru Inaba, Masayuki Baba, Soroku Yagihash. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses development of neuropathy in diabetic rodents: effects on peripheral sensory nerve function, structure and molecular changes. Journal of neurochemistry. vol 136. issue 4. 2019-11-20. PMID:26603140. |
the results suggest close association of neuropathy development with impaired signaling of insulin and glp-1 in diabetic rodents. |
2019-11-20 |
2023-08-13 |
mouse |
| Kentaro Tsuboi, Hiroki Mizukami, Wataru Inaba, Masayuki Baba, Soroku Yagihash. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses development of neuropathy in diabetic rodents: effects on peripheral sensory nerve function, structure and molecular changes. Journal of neurochemistry. vol 136. issue 4. 2019-11-20. PMID:26603140. |
dpp-iv inhibitor, vildagliptin, corrected insulin resistance and improved neuropathy irrespective of blood glucose via augmented action of glp-1. |
2019-11-20 |
2023-08-13 |
mouse |
| Andreas Lindqvist, Liliya Shcherbina, Ann-Helen Thorén Fischer, Nils Wieru. Ghrelin Is a Regulator of Glucagon-Like Peptide 1 Secretion and Transcription in Mice. Frontiers in endocrinology. vol 8. 2019-11-20. PMID:28674521. |
in this study, we studied the effect of ghrelin on glp-1, gip, and insulin secretion during an oral glucose tolerance test (ogtt) in mice. |
2019-11-20 |
2023-08-13 |
mouse |
| Ivan N Tyurenkov, Denis V Kurkin, Dmitry A Bakulin, Elena V Volotova, Mikhail A Chafeev, Alexey V Smirnov, Evgeny I Morkovi. ZB-16, a Novel GPR119 Agonist, Relieves the Severity of Streptozotocin-Nicotinamide-Induced Diabetes in Rats. Frontiers in endocrinology. vol 8. 2019-11-20. PMID:28736546. |
the purpose of this work was to assess the influence of novel gpr119 agonist zb-16 on the glucose utilization, insulin, and glucagon-like peptide-1 (glp-1) secretion and the morphology of pancreas in rats with streptozotocin-nicotinamide-induced diabetes. |
2019-11-20 |
2023-08-13 |
rat |
| V de Brouckère, L Pla. [Diabetes care pathways and the diabetic convention in 2017]. Revue medicale de Bruxelles. vol 38. issue 4. 2019-11-20. PMID:28981239. |
only those patients receiving a parenteral treatment with insulin or glp-1 (glucose like peptide-1) analogues and those patients whose hba1c target is not achieved with oral glucose lowering treatment and for whom parenteral treatments taken into consideration can enroll in a ct. |
2019-11-20 |
2023-08-13 |
Not clear |